Twenty-four months of follow-up in women with rebound-associated vertebral fractures after discontinuation of denosumab: a single-centre case series

ConclusionIn this series of patients with RAVFs, we did not observe any new fractures and the BMD remained stable after 24  months of RT. Future studies are needed to evaluate the most suitable treatment approach after RAVFs but these preliminary data suggest that all denosumab, zoledronate and teriparatide might be adequate options.
Source: Osteoporosis International - Category: Orthopaedics Source Type: research